Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release (Revised) Aug 24 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a revised press release announcing final approval from the USFDA for Zinc Sulfate Injection Pharmacy Bulk Package Vials. The approval covers multiple formulations of the injection, which is used for parenteral nutrition when oral intake is not feasible. The drug will be manufactured at Zydus's facility in Jarod, and it had significant annual sales in the United States.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a revised press release dated August 24, 2023, titled "Zydus receives final approval from the USFDA for Zinc Sulfate Injection USP, 10 mg/10 mL (1 mg/mL), 30 mg/10 mL (3 mg/mL), and 25 mg/5 mL (5 mg/mL) Pharmacy Bulk Package Vials".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases